Alex Philippidis

UCB has dedicated the Rowen, GA, site where it plans to build a $2 billion biologics manufacturing campus that is set to open as the Belgian-based drug developer's first U.S. manufacturing site.

Diasome is preparing to advance its HDV-insulin formulation into pivotal studies after generating positive Phase IIb data earlier this year and presenting it at two conferences earlier this fall.

Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, Liquidia (Nasdaq: LQDA) shares finally began bouncing back this past week thanks to a settlement with United Therapeutics (Nasdaq: UTHR) that drew mixed conclusions from four analysts about which company won out long-term.

Roche and Hansoh Pharmaceutical Group have launched their second collaboration focused on developing cancer-fighting antibody-drug conjugates (ADCs), a partnership that could generate more than $15 billion for the Shanghai-based drug developer.

Conducting the first genome-wide association study and analysis based on a new definition of clinical obesity, a research team has identified genetic signals that differed substantially from those associated with body mass index (BMI)—yet showed stronger connections to cardiovascular health.

The University of Washington (UW) School of Medicine Institute for Protein Design (IPD) has partnered with Nvidia to develop an open, generative model that uses biomolecular reasoning designed to improve how well researchers can design new proteins with specific functions.

An entity of Swedish private equity firm EQT has agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) cash, both said today, in a deal that would take private the global life-sciences tools, diagnostics, and workflow solutions provider following on-and-off takeover attempts over nearly seven years.

Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with GEN Edge (edited for length and clarity).

Anthropic plans to expand its growing presence in life sciences by investing further in knowledge, talent, partnerships, and additional acquisitions, the artificial intelligence (AI) giant disclosed in its long-awaited initial public offering (IPO) filing.

Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated with its lead candidate in a Phase IIa trial died—though one death was unrelated to the treatment.